Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.

Bartlett, J B; Michael, A; Clarke, I A; Dredge, K; Nicholson, S; Kristeleit, H; Polychronis, A; Pandha, H; Muller, G W; Stirling, D I; Zeldis, J; Dalgleish, A G

Bartlett, J B; Michael, A; Clarke, I A; Dredge, K; Nicholson, S; Kristeleit, H; Polychronis, A; Pandha, H; Muller, G W; Stirling, D I; Zeldis, J; Dalgleish, A G.

Affiliation

Bartlett JB; Division of Oncology, Department of Cellular & Molecular Medicine, St George's Hospital Medical School, Cranmer Terrace, Tooting, London SW17 ORE, UK.

Br J Cancer ; 90(5): 955-61, 2004 Mar 08.

Article in En | MEDLINE | ID: mdl-14997189

Subject(s)

Angiogenesis Inhibitors/therapeutic use; Melanoma/drug therapy; Skin Neoplasms/drug therapy; Thalidomide/analogs & derivatives; Thalidomide/therapeutic use; Adolescent; Adult; Aged; Aged, 80 and over; Cytokines/blood; Female; Fibroblast Growth Factor 2/metabolism; Humans; Immunization; Lenalidomide; Male; Maximum Tolerated Dose; Melanoma/secondary; Middle Aged; Neoplasms/drug therapy; Neoplasms/pathology; Safety; Skin Neoplasms/pathology; T-Lymphocytes/metabolism; Vascular Endothelial Growth Factor A/metabolism

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Thalidomide / Angiogenesis Inhibitors / Melanoma Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2004 Document type: Article Affiliation country: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google